PBM

Psyence Biomedical Ltd

5.40

Sep 11 • 3:59 PM ET +0.43 (8.65%)

5.50

Aftermarket • 7:30 PM ET +0.10 (1.85%)

Healthcare Biotechnology Canada Nano NASD

Peers: APRE BCDA BIVI CVM KAPA KPRX LNAI NEUP CALC GOVX

| Held by: PSIL

Scroll to Statements

Index	-
Market Cap	20.60M
Enterprise Value	13.40M
Income	-
Sales	-
Book/sh	39.62
Cash/sh	1.89
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Dec 10, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.14
P/C	2.86
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.09
Current Ratio	8.09
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-105.54%
Sales Y/Y TTM	-
EPS Q/Q	-23614.18%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	32.93%
Insider Trans	0.00%
Inst Own	9.66%
Inst Trans	6.97%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	23.78%
SMA50	49.15%
SMA200	20.53%
Trades

Shs Outstand	3.81M
Shs Float	2.56M
Short Float	0.54%
Short Ratio	0.18
Short Interest	0.01M
52W High	34.62 -84.40%
52W Low	1.92 181.25%
Volatility	9.79% 9.96%
ATR (14)	0.36
RSI (14)	79.69
Beta	1.68
Rel Volume	1.71
Avg Volume	78.87K
Volume	134,486

Perf Week	21.90%
Perf Month	61.19%
Perf Quarter	54.73%
Perf Half Y	119.51%
Perf YTD	14.68%
Perf Year	-73.33%
Perf 3Y	-99.99%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.97
Price	5.40
Change %	8.65%

Aug-18-26 05:23PM	Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development (GlobeNewswire) +23.82% -8.28%
May-15-26 09:15AM	Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing (GlobeNewswire)
Apr-27-26 09:16AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -10.87%
Apr-23-26 07:00AM	Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder (GlobeNewswire)
Apr-20-26 07:42AM	Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source (GlobeNewswire) +48.68%
09:15AM	Loading…
Apr-17-26 09:15AM	Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine (GlobeNewswire) +29.47%
Apr-14-26 01:17PM	Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement (TMX Newsfile) +5.73%
Apr-08-26 09:15AM	Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities (GlobeNewswire)
Mar-11-26 09:15AM	Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Mar-03-26 09:15AM	Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial (GlobeNewswire)
Feb-20-26 05:20PM	Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment (GlobeNewswire) -10.80%
Feb-17-26 09:15AM	Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders (GlobeNewswire) -9.71%
Feb-13-26 06:30PM	Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway (GlobeNewswire) +9.96%
Feb-11-26 09:15AM	Psyence BioMed Announces Settlement of Shareholder Litigation (GlobeNewswire) -6.92%
06:30PM	Loading…
Jan-28-26 06:30PM	Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split (GlobeNewswire) +22.01% -6.42%
Jan-22-26 01:42PM	Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 (GlobeNewswire) -12.69%
Jan-20-26 07:19AM	Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date (GlobeNewswire)
Jan-14-26 07:00PM	Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split (GlobeNewswire) -13.90%
Jan-12-26 08:30AM	Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity (GlobeNewswire)
Jan-05-26 09:15AM	Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash (GlobeNewswire) -9.19%
Dec-19-25 07:00AM	Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial (GlobeNewswire) -31.51%
Dec-09-25 07:00AM	Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science (GlobeNewswire) -5.92%
Dec-01-25 08:38AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +5.54%
Nov-25-25 07:00AM	Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program (GlobeNewswire) +5.96%
Nov-20-25 07:00AM	Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets (GlobeNewswire) -38.35%
Nov-12-25 07:00AM	Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs (GlobeNewswire)
Nov-06-25 07:00AM	Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care (GlobeNewswire) -7.10%
Nov-03-25 07:00AM	Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment (GlobeNewswire) -5.06%
Sep-02-25 03:53AM	Psyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine Production (Insider Monkey)
08:00AM	Loading…
Aug-28-25 08:00AM	Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 (GlobeNewswire)
Aug-04-25 08:30AM	Corporate Update, August 2025 (GlobeNewswire) +92.37%
Jul-31-25 07:30AM	Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production (GlobeNewswire) -6.85%
Jun-25-25 05:00PM	PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares (GlobeNewswire)
Jun-18-25 05:36PM	PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares (GlobeNewswire)
08:30AM	Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 (Newsfile)
Jun-17-25 08:00AM	Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements (Newsfile) +16.61%
May-27-25 07:30AM	Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial (Newsfile)
May-01-25 07:30AM	Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split (Newsfile)
Apr-17-25 07:17PM	Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Newsfile) -5.74% -7.65%
09:39AM	Psyence Group Announces Share Consolidation (GlobeNewswire)
Apr-15-25 08:30AM	Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement (Newsfile)
Apr-08-25 08:00AM	Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia (Newsfile)
Mar-31-25 08:00AM	Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing (Newsfile)
Mar-25-25 10:47AM	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein (GlobeNewswire) -6.70%
Mar-18-25 08:30AM	Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein (Newsfile)
Mar-10-25 11:18AM	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board (GlobeNewswire)
Feb-26-25 08:00AM	Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board (GlobeNewswire) +10.74%
Dec-27-24 04:05PM	Psyence Biomed Announces Closing of $2.0 Million Private Placement (GlobeNewswire) -5.44% -5.75%
Dec-24-24 05:57PM	Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position (TipRanks)
Dec-23-24 08:00AM	Psyence Biomed Announces $2.0 Million Private Placement (GlobeNewswire) -25.16%
07:30AM	Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements (GlobeNewswire)
Dec-17-24 08:37AM	Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial (GlobeNewswire) -5.41%
02:30AM	Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial (Newsfile)
Dec-11-24 07:35AM	Psyence Biomedical executes binding agreements with Optimi Health (TipRanks)
Dec-10-24 07:30AM	Psyence Biomed Executes Binding Agreements with Optimi Health Corp. (GlobeNewswire)
Dec-06-24 11:06AM	Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations (GlobeNewswire) -10.23%
Dec-03-24 07:30AM	Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress (GlobeNewswire) -12.69%
Nov-24-24 08:44PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-20-24 07:30AM	Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing (GlobeNewswire)
Nov-19-24 04:05PM	Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation (GlobeNewswire)
Nov-12-24 04:30PM	Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq (GlobeNewswire) -7.66% -19.60%
Oct-31-24 09:30AM	Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs (GlobeNewswire) -26.38%
07:30AM	Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs (GlobeNewswire)
Oct-25-24 09:42AM	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care (GlobeNewswire)
Oct-24-24 07:00AM	Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care (GlobeNewswire) -12.07%
Oct-17-24 07:00AM	Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development (GlobeNewswire)
Oct-14-24 10:43AM	Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical (GlobeNewswire)
Oct-04-24 04:05PM	Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant (GlobeNewswire) +5.89%
Sep-20-24 11:20AM	Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs (GlobeNewswire) -6.11%
Sep-19-24 07:30AM	Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs (GlobeNewswire) -8.13%
Sep-18-24 09:30AM	Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones (GlobeNewswire) +11.20%
Sep-16-24 09:31AM	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care (GlobeNewswire) -18.59%
07:30AM	Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones (GlobeNewswire)
Sep-13-24 04:30PM	Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq (GlobeNewswire)
Sep-09-24 07:30AM	Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care (GlobeNewswire)
Sep-06-24 07:30AM	Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant (GlobeNewswire) -17.17%
Sep-04-24 07:30AM	Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs) (GlobeNewswire) -34.99%
Aug-30-24 07:00AM	Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC (GlobeNewswire)
Aug-27-24 04:05PM	Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 (GlobeNewswire)
Aug-13-24 07:30AM	Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development (Newsfile)
Jul-31-24 04:05PM	Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC (GlobeNewswire)
Jul-26-24 09:30AM	Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial (GlobeNewswire)
Jul-24-24 04:05PM	Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial (GlobeNewswire) +53.30%
Jul-23-24 02:14PM	US home sales dip, Secret Service director resigns: Catalysts (Yahoo Finance Video)
Jul-03-24 08:34PM	Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -35.00%
May-17-24 07:00AM	Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase (GlobeNewswire)
Apr-17-24 08:00AM	Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR) (GlobeNewswire)
Apr-16-24 11:01AM	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire) -12.61%
11:01AM	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
Apr-08-24 08:00AM	Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
08:00AM	Psyence Biomed Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
08:00AM	Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (PR Newswire)
Mar-26-24 11:06AM	Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business (GlobeNewswire)
Mar-18-24 04:05PM	Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin (GlobeNewswire)
Mar-15-24 04:30PM	Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares (GlobeNewswire) -18.87%
Mar-12-24 11:15AM	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study (GlobeNewswire) -30.51%
07:00AM	Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones (GlobeNewswire)
Mar-11-24 07:00AM	Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division (GlobeNewswire) -16.11%

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on February 25, 2021 and is headquartered in Toronto, Canada.

Co-FounderMr. Jody Aufrichtig

CFO & DirectorMr. Warwick Ron Corden-Lloyd

Global Head of Clinical DevelopmentDr. Neil Maresky M.D.

General CounselMs. Taryn Vos

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBM

Psyence Biomedical Ltd

Upgrade your Finviz experience